期刊文献+

高表达OAZI-1增加小鼠黑素瘤B16-F1细胞对多胺类似物CPENSpm的敏感性

OAZI-1 overexpression increases sensitivity of mouse melanoma B16-F1 cells to polyamine analog CPENSpm
下载PDF
导出
摘要 目的检测高表达OAZI-1的小鼠黑素瘤B16-F1细胞对抗癌药物多胺类似物CPENSpm敏感性的影响并探讨其作用机制。方法高表达OAZI-1的B16-F1细胞经CPENSpm处理后,MTT法检测细胞增殖;QT-RT-PCR检测细胞内OAZI-1、ODC和OAZ的mRNA表达水平;反相高效液相色谱法检测细胞内多胺含量;化学发光法分析细胞内SMO酶活性。结果高表达OAZI-1显著增加B16-F1细胞对CPENSpm的敏感性,QT-RT-PCR结果显示,OAZI-1高表达增加ODCmRNA但降低OAZ mRNA水平,CPENSpm处理对ODC和OAZ的mRNA水平无进一步影响。与对照细胞相比,CPENSpm处理能更显著性地降低OAZI-1高表达细胞中的多胺含量,同时更强地诱导SMO酶的活性。结论 CPENSpm处理能在更大程度上耗竭OAZI-1高表达的B16-F1细胞中的多胺,由此对该肿瘤细胞显示出更大的细胞毒性。 Objective To detect the influence of ornithine antizyme inhibitor-1(OAZI-1) overexpression on the sensitivity of mouse melanoma B16-F1 cells to polyamine analog CPENSpm,and to study the underlying mechanism.Methods B16-F1 cells with OAZI-1 overexpression were treated with CPENSpm.MTT assay was used to detect cell proliferation.QT-RT-PCR was used to determine the mRNA expression levels of OAZI-1,ornithine decarboxylase(ODC) and ornithine decarboxylase antizyme(OAZ) in B16-F1 cells.RP-HPLC was used to determine the polyamine content in B16-F1 cells.Chemiluminescence assay was used to determine the activity of spermine oxidase(SMO) in B16-F1 cells.Results The MTT results showed that OAZI-1 overexpression increased the sensitivity of B16-F1 cells to CPENSpm significantly.The QT-RT-PCR results showed an increased mRNA expression level of ODC but a decreased mRNA expression level of OAZ in B16-F1 cells with OAZI-1 overexpression(B16/over).No further changes of the mRNA expression levels of ODC and OAZ were detected in both B16/over cells and control cells(B16/3.1) after being treated with CPENSpm for 24 h.Compared with those in B16/3.1 cells,the polyamine content was lowered significantly,and the SMO activity was increased in B16/over cells after 24-h CPENSpm treatment.Conclusion CPENSpm treatment can largely deplete intracellular polyamine in B16-F1 cells with OAZI-1 overexpression,resulting in increased cytotoxicity on those tumor cells.
出处 《第三军医大学学报》 CAS CSCD 北大核心 2011年第16期1687-1690,共4页 Journal of Third Military Medical University
基金 国家自然科学基金(30772590)~~
关键词 抗酶抑制因子-1 多胺类似物CPENSpm 多胺 黑素瘤细胞 ornithine antizyme inhibitor-1 CPENSpm polyamine melanoma cells
  • 相关文献

参考文献15

  • 1Agostinelli E, Marques M P, Calheiros R, et al. Polyamines: fundamental characters in chemistry and biology [ J ]. Amino Acids, 2010, 38(2) : 393 -403.
  • 2Casero R A Jr, Marton L J. Targeting polyamine metabolism and function in cancer and other hypexrproliferative diseases[ J]. Nat Rev Drug Discov, 2007, 6 (5) : 373 - 390.
  • 3Pegg A E. Regulation of ornithine decarboxylase [ J ]. J Biol Chem 2006, 281 (21) : 14529 - 14532.
  • 4Persson L. Polyamine homoeostasis[ J]. Essays Biochem, 2009, 46 11 -24.
  • 5Kahana C. Antizyme and antizyme inhibitor, a regulatory tango [ J ]. Cell Mol Life Sci, 2009, 66(15): 2479-2488.
  • 6Kahana C. Regulation of cellular polyamine levels and cellular prolifer ation by antizyme and antizyme inhibitor[ J ]. Essays Biochem, 2009 46:47-61.
  • 7Lopez-Contreras A J, Ramos-Molina B, Cremades A, et al. Antizyme inhibitor 2 : molecular, cellular and physiological aspects [ J ]. Amino Acids, 2010, 38(2): 603-611.
  • 8Kim S W, Mangold U, Waghorne C, et al. Regulation of eell proliferation by the antizyme inhibitor: evidence for an antizyme-independent mechanism[J]. JCellSci, 2006, 119(Pt 12): 2583 -2591.
  • 9Keren-Paz A, Bercovich Z, Kahana C. Antizyme inhibitor: a defective ornithine decarboxylase or a physiological regulator of polyamine biosyn- thesis and cellular proliferation[ J ]. Biochem Soc Trans, 2007, 35 ( Pt 2): 311 -313.
  • 10Murakami Y, Suzuki J, Samejima K, et al. The change of antizyme inhibitor expression and its possible role during mammalian cell cycle [J]. Exp Cell Res, 2009, 315(13): 2301 -2311.

二级参考文献25

  • 1赵雅君,王丽娜,李鸿珠,张力,徐长庆,孙轶华,Wang Rui.大鼠心肌多胺代谢限速酶ODC、SSAT活性分析[J].中国药理学通报,2005,21(5):555-559. 被引量:9
  • 2Babbar N, Murray-Stewart T, Casero R A Jr. Inflammation and polyamine catabolism: the good, the bad and the ugly [ J ]. Biochem Soc Trans, 2007, 35 ( Pt 2) : 300 - 304.
  • 3Moinard C, Cynober L, de-Bandt J P. Polyamines: metabolism and implications in human diseases[J]. Clin Nutr, 2005, 24(2) : 184 - 197.
  • 4Wang Y, Casero R A Jr. Mammalian polyarnine catabolism: a therapeutic target, a pathological problem, or both? [J]. J Biochem (Tokyo), 2006, 139(1): 17-25.
  • 5Casero R A Jr, Marton L J. Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases[ J]. Nat Rev Drug Discov, 2007, 6 (5) : 373 - 390.
  • 6Shantz L M, Levin V A. Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential [ J ]. Amino Acids, 2007, 33 (2) : 213 -223.
  • 7Wallace H M, Fraser A V, Hughes A. A perspective of polyamine metabolism[J]. Bioehem J, 2003, 376(Pt 1) : 1 - 14.
  • 8Simoneau A R, Gerner E W, Nagle R, et al. The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: resuits of a year-long phase IIb randomized placebo-controlled chemoprevention trial[ J ]. Cancer Epidemiol Biomarkers Prey, 2008, 17 (2) : 292 - 299.
  • 9Jiang X, Wang X. Cytochrome C-mediated apoptosis[ J]. Annu Rev Biochem, 2004, 73: 87- 106.
  • 10Wang Y, Hacker A, Murray-Stewart T, et al. Induction of human spermine oxidase SMO ( PAOhl ) is regulated at the levels of new mRNA synthesis, mRNA stabilization and newly synlhesized protein [J]. BiochemJ, 2005,386(Pt3): 543-547.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部